ERBB3 and metastatic malignant neoplasm in the lymph nodes: As shown in Table 2, the correlation rates between primary lesion and lymph node metastases were only 67.1% (53/79) for EGFR, 63.3% (50/79) for HER2, and 74.7% (59/79) for HER3.